newsfilter
← Latest News
PR Newswire·

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

SOPH
  • SOPHiA GENETICS announced the commencement of a proposed underwritten public offering of its ordinary shares.
  • The company expects to grant underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price less the underwriting discount.
  • All ordinary shares in the proposed offering will be sold by the company.
  • The offering is subject to market conditions with no assurance regarding completion, size, or terms.
  • TD Cowen is acting as the lead book-running manager for the offering.
  • A registration statement on Form F-3 (File No. 333-289266) was declared effective by the SEC on August 15, 2025.
  • The offering may be conducted only via a prospectus supplement relating to the offering and an accompanying prospectus.
  • Copies of the preliminary prospectus supplement and accompanying prospectus will be available on the SEC website or by contacting TD Securities (USA) LLC.
  • The press release does not constitute an offer to sell securities in any state or jurisdiction where such sale is unlawful prior to registration.
  • Securities will not be offered, solicited, sold, or advertised in Switzerland under the Swiss Financial Services Act, nor will they be listed on the SIX Swiss Exchange.
  • SOPHiA GENETICS is an AI-native healthcare technology company that created the SOPHiA DDM™ platform to analyze genomic data for global institutions.
  • The release includes forward-looking statements regarding the proposed offering that are subject to risks and uncertainties.